An Open-label, Non-randomized, 2-arm, 2-period Fixed Sequence Phase 1 Study to Evaluate the Potential Inhibition of Nitisinone on Cytochrome P450 2C9, 2D6, and 2E1 and the Organic Anion Transporters OAT1 and OAT3 in Healthy Volunteers

Trial Profile

An Open-label, Non-randomized, 2-arm, 2-period Fixed Sequence Phase 1 Study to Evaluate the Potential Inhibition of Nitisinone on Cytochrome P450 2C9, 2D6, and 2E1 and the Organic Anion Transporters OAT1 and OAT3 in Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Aug 2017

At a glance

  • Drugs Nitisinone (Primary) ; Chlorzoxazone; Furosemide; Metoprolol; Tolbutamide
  • Indications Inborn error metabolic disorders; Tyrosinaemia type I
  • Focus Pharmacokinetics
  • Sponsors Swedish Orphan Biovitrum
  • Most Recent Events

    • 09 Aug 2017 Status changed from active, no longer recruiting to completed.
    • 21 Jul 2017 Planned End Date changed from 19 Jul 2017 to 25 Jul 2017.
    • 30 Jun 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top